These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31834957)

  • 1. Oral Iron for Prevention and Treatment of Rickets and Osteomalacia in Autosomal Dominant Hypophosphatemia.
    Högler W; Kapelari K
    J Bone Miner Res; 2020 Feb; 35(2):226-230. PubMed ID: 31834957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypophosphatemic rickets and short stature.
    Davis K; Imel EA; Kelley J
    J Bone Miner Res; 2024 Aug; 39(7):821-825. PubMed ID: 38988138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralized tissues in hypophosphatemic rickets.
    Robinson ME; AlQuorain H; Murshed M; Rauch F
    Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.
    Menon LP; Weinstein RS
    Bone; 2020 Feb; 131():115137. PubMed ID: 31756522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets.
    Imel EA; Liu Z; Coffman M; Acton D; Mehta R; Econs MJ
    J Bone Miner Res; 2020 Feb; 35(2):231-238. PubMed ID: 31652009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to Hypophosphatemic Rickets.
    Ackah SA; Imel EA
    J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
    Bai X; Levental M; Karaplis AC
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2777-2783. PubMed ID: 35896139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.
    Farrow EG; Yu X; Summers LJ; Davis SI; Fleet JC; Allen MR; Robling AG; Stayrook KR; Jideonwo V; Magers MJ; Garringer HJ; Vidal R; Chan RJ; Goodwin CB; Hui SL; Peacock M; White KE
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):E1146-55. PubMed ID: 22006328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
    Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
    Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rickets guidance: part II-management.
    Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
    Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.
    Wolf M; White KE
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):411-9. PubMed ID: 24867675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
    Fukumoto S
    Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
    Michigami T
    Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets.
    Razali NN; Hwu TT; Thilakavathy K
    J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1009-17. PubMed ID: 25894638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron deficiency plays essential roles in the trigger, treatment, and prognosis of autosomal dominant hypophosphatemic rickets.
    Liu C; Li X; Zhao Z; Chi Y; Cui L; Zhang Q; Ping F; Chai X; Jiang Y; Wang O; Li M; Xing X; Xia W
    Osteoporos Int; 2021 Apr; 32(4):737-745. PubMed ID: 32995940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.